Takeda's Millennium re-ups with Presage on cancer drug combo effort

Whatever Cambridge, MA-based Millennium learned over the past two years it's been collaborating with Presage Biosciences, the experience must have been rewarding. The Takeda sub has followed up with an expanded pact to use the Seattle-based company, a brainchild of Jim Olson's at the Hutch, to explore the potential of more cancer drug combinations. Presage's technology is designed to identify the most promising combination therapies, a big field in oncology these days. Presage gets an unspecified package including an upfront and milestones, but the exact terms of being kept under wraps--just like their first deal. Release

Suggested Articles

The deal gives J&J a stake in the development and commercialization of anticoagulants including phase 2-ready secondary stroke candidate BMS-986177.

Boehringer gained the global rights to OSE's SIRP-alpha antagonist, which is in development for solid tumors.

Lilly is diving into encapsulated beta cell treatments, designed to restore insulin production in patients with Type 1 diabetes.